FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319759466> ?p ?o ?g. }

• W4319759466 endingPage "109505" @default.
• W4319759466 startingPage "109505" @default.
• W4319759466 abstract "BackgroundThis clinical trial aims at investigate the feasibility of CTV-omitted, positron-emission tomography computed tomography (PET-CT) combined with intensity-modulated radiation therapy (IMRT) for unresectable stage III NSCLC.Methods and MaterialsThis was a single-center, phase II clinical trial initiated in July 2016. Patients with unresectable stage III NSCLC undergoing routine IMRT were randomly enrolled into the study group (CTV-omitted under PET-CT guidance) and the control group (CTV-delineated). Patients received platinum-based dual-drug concurrent chemoradio therapy. In the study group, the PGTV dose was 60 Gy given in 30 daily 2 Gy fractions; in the control group, the PCTV dose was 54 Gy given in 30 daily 1.8 Gy fractions, and the PGTV dose was 60 Gy given in 30 daily 2 Gy fractions. The primary endpoint was the incidence of radiation respiratory events or esophagitis with grade 3 or higher. The secondary endpoints included objective response rate (ORR), locate control rate, progression-free survival (PFS), failure pattern and overall survival (OS).ResultsA total of 90 patients were enrolled between July 2016 and March 2019. The incidence of radiation respiratory events or esophagitis with grade 3 or higher was 11.1 % in the study group, significantly lower than the rate of 28.9 % in the control group (P = 0.035), basically due to the reduced irradiated volumes of the lungs and esophagus in the study group. The median PFS was 9.0 months versus 10.0 months (P = 0.597), and the median OS 31.0 months versus 26.0 months (P = 0.489) in the study group and the control group, respectively. The failure pattern was not significantly different between the two groups (P = 0.826).ConclusionOmitting the CTV under PET-CT guidance has high feasibility to reduce severe radiation associated toxicity in IMRT for unresectable stage III NSCLC, without compromising the efficacy." @default.
• W4319759466 created "2023-02-11" @default.
• W4319759466 creator A5003514746 @default.
• W4319759466 creator A5012314133 @default.
• W4319759466 creator A5020724945 @default.
• W4319759466 creator A5021189389 @default.
• W4319759466 creator A5033704842 @default.
• W4319759466 creator A5035296421 @default.
• W4319759466 creator A5047063645 @default.
• W4319759466 creator A5071074966 @default.
• W4319759466 creator A5088138197 @default.
• W4319759466 date "2023-04-01" @default.
• W4319759466 modified "2023-10-01" @default.
• W4319759466 title "Feasibility of omitting the clinical target volume under PET-CT guidance in unresectable stage III non-small-cell lung cancer: A phase II clinical trial" @default.
• W4319759466 cites W1930920471 @default.
• W4319759466 cites W1968899146 @default.
• W4319759466 cites W1970625453 @default.
• W4319759466 cites W1972885575 @default.
• W4319759466 cites W1992291788 @default.
• W4319759466 cites W2005026523 @default.
• W4319759466 cites W2028244710 @default.
• W4319759466 cites W2028688614 @default.
• W4319759466 cites W2049642953 @default.
• W4319759466 cites W2073000887 @default.
• W4319759466 cites W2087451637 @default.
• W4319759466 cites W2091988977 @default.
• W4319759466 cites W2098564635 @default.
• W4319759466 cites W2099040029 @default.
• W4319759466 cites W2104355587 @default.
• W4319759466 cites W2134640829 @default.
• W4319759466 cites W2139248078 @default.
• W4319759466 cites W2152729363 @default.
• W4319759466 cites W2263280562 @default.
• W4319759466 cites W2401873646 @default.
• W4319759466 cites W2522150959 @default.
• W4319759466 cites W2621243763 @default.
• W4319759466 cites W2753065806 @default.
• W4319759466 cites W2766131025 @default.
• W4319759466 cites W2768242998 @default.
• W4319759466 cites W2770230492 @default.
• W4319759466 cites W2795351448 @default.
• W4319759466 cites W2806946493 @default.
• W4319759466 cites W2808607186 @default.
• W4319759466 cites W2892044801 @default.
• W4319759466 cites W2966463872 @default.
• W4319759466 cites W3011596192 @default.
• W4319759466 cites W3046176175 @default.
• W4319759466 cites W4211243765 @default.
• W4319759466 doi "https://doi.org/10.1016/j.radonc.2023.109505" @default.
• W4319759466 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36764460" @default.
• W4319759466 hasPublicationYear "2023" @default.
• W4319759466 type Work @default.
• W4319759466 citedByCount "1" @default.
• W4319759466 countsByYear W43197594662023 @default.
• W4319759466 crossrefType "journal-article" @default.
• W4319759466 hasAuthorship W4319759466A5003514746 @default.
• W4319759466 hasAuthorship W4319759466A5012314133 @default.
• W4319759466 hasAuthorship W4319759466A5020724945 @default.
• W4319759466 hasAuthorship W4319759466A5021189389 @default.
• W4319759466 hasAuthorship W4319759466A5033704842 @default.
• W4319759466 hasAuthorship W4319759466A5035296421 @default.
• W4319759466 hasAuthorship W4319759466A5047063645 @default.
• W4319759466 hasAuthorship W4319759466A5071074966 @default.
• W4319759466 hasAuthorship W4319759466A5088138197 @default.
• W4319759466 hasBestOaLocation W43197594661 @default.
• W4319759466 hasConcept C120665830 @default.
• W4319759466 hasConcept C121332964 @default.
• W4319759466 hasConcept C126322002 @default.
• W4319759466 hasConcept C126838900 @default.
• W4319759466 hasConcept C146357865 @default.
• W4319759466 hasConcept C151730666 @default.
• W4319759466 hasConcept C203092338 @default.
• W4319759466 hasConcept C2776256026 @default.
• W4319759466 hasConcept C2777819096 @default.
• W4319759466 hasConcept C2779134260 @default.
• W4319759466 hasConcept C2779920096 @default.
• W4319759466 hasConcept C2989005 @default.
• W4319759466 hasConcept C43270747 @default.
• W4319759466 hasConcept C509974204 @default.
• W4319759466 hasConcept C535046627 @default.
• W4319759466 hasConcept C61511704 @default.
• W4319759466 hasConcept C71924100 @default.
• W4319759466 hasConcept C86803240 @default.
• W4319759466 hasConceptScore W4319759466C120665830 @default.
• W4319759466 hasConceptScore W4319759466C121332964 @default.
• W4319759466 hasConceptScore W4319759466C126322002 @default.
• W4319759466 hasConceptScore W4319759466C126838900 @default.
• W4319759466 hasConceptScore W4319759466C146357865 @default.
• W4319759466 hasConceptScore W4319759466C151730666 @default.
• W4319759466 hasConceptScore W4319759466C203092338 @default.
• W4319759466 hasConceptScore W4319759466C2776256026 @default.
• W4319759466 hasConceptScore W4319759466C2777819096 @default.
• W4319759466 hasConceptScore W4319759466C2779134260 @default.
• W4319759466 hasConceptScore W4319759466C2779920096 @default.
• W4319759466 hasConceptScore W4319759466C2989005 @default.
• W4319759466 hasConceptScore W4319759466C43270747 @default.
• W4319759466 hasConceptScore W4319759466C509974204 @default.
• W4319759466 hasConceptScore W4319759466C535046627 @default.

• next